FDA approved drugs in Feb., 2013
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
PharmaSages_<strong>Feb</strong> 13 update<br />
• Roche/Genentech's breakthrough T-DM1 w<strong>in</strong>s <strong>FDA</strong><br />
approval for breast cancer<br />
• Celgene grabs <strong>FDA</strong> approval for new multiple<br />
myeloma pill, Pomalyst<br />
• Hyperion w<strong>in</strong>s its first <strong>FDA</strong> approval for its drug<br />
Ravicti, a treatment for manag<strong>in</strong>g genetic<br />
conditions known as urea cyclic disorders<br />
• Otsuka Pharmaceutical and Lundbeck get approval<br />
on the two drugmakers' once-monthly version of<br />
the big-sell<strong>in</strong>g schizophrenia drug Abilify<br />
• Denmark's Lundbeck w<strong>in</strong>s European approval for<br />
the alcohol dependence drug Sel<strong>in</strong>cro
Contact us<br />
Ajay Shrivastava, CEO<br />
PharmaSages<br />
58 Magnolia Lane<br />
Pr<strong>in</strong>ceton, NJ 08540<br />
Phone: (609)423-7602<br />
E-mail:asbiopro@pharmasages.com<br />
Web: www.pharmasages.com
Change language